UA112564C2 - 1h-індазол-3-карбоксамідні сполуки як інгібітори глікогенсинтаза-кінази 3-бета - Google Patents

1h-індазол-3-карбоксамідні сполуки як інгібітори глікогенсинтаза-кінази 3-бета

Info

Publication number
UA112564C2
UA112564C2 UAA201406961A UAA201406961A UA112564C2 UA 112564 C2 UA112564 C2 UA 112564C2 UA A201406961 A UAA201406961 A UA A201406961A UA A201406961 A UAA201406961 A UA A201406961A UA 112564 C2 UA112564 C2 UA 112564C2
Authority
UA
Ukraine
Prior art keywords
disorders
indazole
beta
carboxamide compounds
kinase inhibitors
Prior art date
Application number
UAA201406961A
Other languages
English (en)
Inventor
Марія Алессандра Алісі
Нікола Каццолла
Патріція Драгоне
Гвідо Фурлотті
Катеріна Мауджері
Розелла Омбрато
Франческа Манчіні
Original Assignee
Ацьєнде Кіміке Ріуніте Анджеліні Франческо А.Чі.Р.А.Ф. С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ацьєнде Кіміке Ріуніте Анджеліні Франческо А.Чі.Р.А.Ф. С.П.А. filed Critical Ацьєнде Кіміке Ріуніте Анджеліні Франческо А.Чі.Р.А.Ф. С.П.А.
Publication of UA112564C2 publication Critical patent/UA112564C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Даний винахід стосується 1Н-індазол-3-карбоксамідних сполук як інгібіторів глікогенсинтаза-кінази 3-бета (GSK-3β) та їх застосування у лікуванні GSK-3β-пов'язаних розладів, таких як, наприклад, (і) інсулінорезистентні розлади; (іі) нейродегенеративні захворювання; (ііі) розлади настрою; (iv) шизофренічні розлади; (v) ракові розлади; (vi) запалення, (vii) розлади, пов'язані із зловживанням психоактивними речовинами; (viii) епілептичні напади; та (іх) невропатичний біль.
UAA201406961A 2012-02-21 2013-07-02 1h-індазол-3-карбоксамідні сполуки як інгібітори глікогенсинтаза-кінази 3-бета UA112564C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12156292 2012-02-21
PCT/EP2013/052400 WO2013124158A1 (en) 2012-02-21 2013-02-07 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors

Publications (1)

Publication Number Publication Date
UA112564C2 true UA112564C2 (uk) 2016-09-26

Family

ID=47739223

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201406961A UA112564C2 (uk) 2012-02-21 2013-07-02 1h-індазол-3-карбоксамідні сполуки як інгібітори глікогенсинтаза-кінази 3-бета

Country Status (27)

Country Link
US (3) US9611249B2 (uk)
EP (1) EP2817302B1 (uk)
JP (1) JP6141331B2 (uk)
KR (1) KR20140130124A (uk)
CN (1) CN104093712B (uk)
AR (1) AR090086A1 (uk)
AU (1) AU2013224302B2 (uk)
BR (1) BR112014018655B1 (uk)
CA (1) CA2860250C (uk)
CY (1) CY1117469T1 (uk)
DK (1) DK2817302T3 (uk)
EA (1) EA024939B1 (uk)
ES (1) ES2564961T3 (uk)
GE (1) GEP20166489B (uk)
HK (1) HK1203930A1 (uk)
HR (1) HRP20160125T1 (uk)
HU (1) HUE026893T2 (uk)
IL (1) IL233824A (uk)
ME (1) ME02353B (uk)
MX (1) MX351287B (uk)
PL (1) PL2817302T3 (uk)
RS (1) RS54567B1 (uk)
SG (2) SG10201701649YA (uk)
SI (1) SI2817302T1 (uk)
SM (1) SMT201600053B (uk)
UA (1) UA112564C2 (uk)
WO (1) WO2013124158A1 (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2817301T1 (sl) 2012-02-21 2016-03-31 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A Uporaba 1H-indazol-3-karboksamidnih spojin kot inhibitorjev glikogen sintaza-kinaze-3beta
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
CA2942687A1 (en) 2014-03-20 2015-09-24 Samumed, Llc 5-substituted indazole-3-carboxamides and preparation and use thereof
EP3468960B1 (en) 2016-06-08 2022-03-23 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
ES2945558T3 (es) * 2018-02-23 2023-07-04 Biosplice Therapeutics Inc Indazol-3-carboxamidas sustituidas con 5-heteroarilo y preparación y uso de las mismas
HRP20220664T1 (hr) 2018-05-07 2022-06-24 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1h-indazol-3-karboksamid spojevi kao inhibitori glikogen sintaza kinaze 3 beta
AU2019280693B2 (en) 2018-06-05 2024-10-10 Actuate Therapeutics Inc. Methods of treating malignant lymphoproliferative disorders
JP7434294B2 (ja) 2018-09-13 2024-02-20 ブリストル－マイヤーズ スクイブ カンパニー キナーゼ阻害剤としてのインダゾールカルボキサミド

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0667867A1 (en) 1992-11-05 1995-08-23 Smithkline Beecham Plc Piperidine derivatives as 5-ht4 receptor antagonists
IT1291569B1 (it) * 1997-04-15 1999-01-11 Angelini Ricerche Spa Indazolammidi come agenti serotoninergici
WO2004014922A1 (en) * 2002-08-10 2004-02-19 Astex Technology Limited 3-(carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
ITMI20030287A1 (it) * 2003-02-18 2004-08-19 Acraf Indazolammidi dotate di attivita' analgesica metodo, per
ITMI20030972A1 (it) 2003-05-15 2004-11-16 Acraf Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
WO2005014554A1 (en) * 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
GB0414438D0 (en) * 2004-06-28 2004-07-28 Syngenta Participations Ag Chemical compounds
AR053662A1 (es) * 2005-01-21 2007-05-16 Astex Therapeutics Ltd Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
EP1692939A1 (en) * 2005-02-19 2006-08-23 Bayer CropScience S.A. Pesticidal substituted piperidines
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
UA99927C2 (uk) 2007-11-12 2012-10-25 Ацьенде Кимике Риуните Анджелини Франческо А.Чи.Р.А.Ф. С.П.А. Медикамент, який є активним при невропатичному болі
US8377968B2 (en) * 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US7947728B1 (en) * 2009-11-11 2011-05-24 Hoffmann-La Roche Inc. Indole and indazole analogs as glycogen synthase activators

Also Published As

Publication number Publication date
BR112014018655A8 (pt) 2017-07-11
RS54567B1 (en) 2016-06-30
CA2860250C (en) 2020-11-10
US9611249B2 (en) 2017-04-04
HRP20160125T1 (hr) 2016-03-11
DK2817302T3 (en) 2016-03-21
MX351287B (es) 2017-10-09
EA024939B1 (ru) 2016-11-30
CA2860250A1 (en) 2013-08-29
EP2817302B1 (en) 2015-12-30
SI2817302T1 (sl) 2016-03-31
HK1203930A1 (zh) 2015-11-06
US10160746B2 (en) 2018-12-25
AU2013224302B2 (en) 2017-03-30
EA201491449A1 (ru) 2014-11-28
JP2015506993A (ja) 2015-03-05
US20150057294A1 (en) 2015-02-26
HUE026893T2 (en) 2016-07-28
KR20140130124A (ko) 2014-11-07
BR112014018655B1 (pt) 2022-02-08
PL2817302T3 (pl) 2016-06-30
WO2013124158A1 (en) 2013-08-29
CN104093712B (zh) 2016-11-09
AR090086A1 (es) 2014-10-15
AU2013224302A1 (en) 2014-07-17
IL233824A0 (en) 2014-09-30
IL233824A (en) 2016-09-29
SMT201600053B (it) 2016-04-29
CN104093712A (zh) 2014-10-08
BR112014018655A2 (uk) 2017-06-20
MX2014009297A (es) 2014-08-27
CY1117469T1 (el) 2017-04-26
GEP20166489B (en) 2016-06-10
SG10201701649YA (en) 2017-04-27
US20170174657A1 (en) 2017-06-22
EP2817302A1 (en) 2014-12-31
US20170157121A1 (en) 2017-06-08
ME02353B (me) 2016-06-20
ES2564961T3 (es) 2016-03-30
JP6141331B2 (ja) 2017-06-07
SG11201403602WA (en) 2014-07-30

Similar Documents

Publication Publication Date Title
UA112564C2 (uk) 1h-індазол-3-карбоксамідні сполуки як інгібітори глікогенсинтаза-кінази 3-бета
UA113189C2 (xx) Застосування 1h-індазол-3-карбоксамідних сполук як інгібіторів глікогенсинтаза-кінази 3-бета
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
PH12015500963A1 (en) Tricyclic fused thiophene derivatives as jak inhibitors
JO3366B1 (ar) مثبطات بيرازوليل كوينوكزالين كاينيز
MX371108B (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
MX346147B (es) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
MX342329B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
EA201391106A1 (ru) Новые гетероциклические производные
EA201691032A1 (ru) Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
PH12014501581A1 (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
MX344590B (es) Inhibidores de f1f0-atpasas de tipo pirazolilguanidina y sus usos terapéuticos.
MX364859B (es) Derivados de imidazopirazinona.
EA201791933A1 (ru) Ингибирование активности olig2
MX369393B (es) Derivados de ftalazina.
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази